147284-02-4

Basic information

• Product Name: Carbamic acid, [4-(2-hydroxyethyl)-2-thiazolyl]-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, [4-(2-hydroxyethyl)-2-thiazolyl]-, 1,1-dimethylethyl ester (9CI)
• CAS NO: 147284-02-4
• Molecular Formula: C₁₀H₁₆N₂O₃S
• Molecular Weight: 244.31
• Mol File: 147284-02-4.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• Density: 1.275±0.06 g/cm3(Predicted)
• PKA: 5.16±0.70(Predicted)
• CAS DataBase Reference: Carbamic acid, [4-(2-hydroxyethyl)-2-thiazolyl]-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [4-(2-hydroxyethyl)-2-thiazolyl]-, 1,1-dimethylethyl ester (9CI)(147284-02-4)
• EPA Substance Registry System: Carbamic acid, [4-(2-hydroxyethyl)-2-thiazolyl]-, 1,1-dimethylethyl ester (9CI)(147284-02-4)

Safety Data

• Hazardous Substances Data: 147284-02-4(Hazardous Substances Data)

Upstream product

• 53266-94-7 ethyl 2-amino-1,3-thiazol-4-acetate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 82548-78-5 ethyl {2-[(tert-butoxycarbonyl)amino]-1,3-thiazol-4-yl}acetate 

Downstream Products

• 215099-32-4 tert-butyl 4-(2-aminoethyl)-1,3-thiazol-2-ylcarbamate 
• 1052722-18-5 {4-[2-(4-fluoro-phenoxy)-ethyl]-thiazol-2-yl}-carbamic acid tert-butyl ester 
• 890093-35-3 4-[2-(4-fluoro-phenoxy)-ethyl]-thiazol-2-ylamine 
• 1357620-82-6 tert-butyl 4-{2-[(4-fluorobenzyl)oxy]ethyl}-1,3-thiazol-2-ylcarbamate 
• 408365-95-7 2-{2-[(tert-butoxycarbonyl)amino]-1,3-thiazol-4-yl}ethyl 4-methylbenzenesulfonate 
• 1357620-80-4 tert-butyl 4-[2-(benzyloxy)ethyl]-1,3-thiazol-2-ylcarbamate 
• 1357620-90-6 4-{2-[(4-fluorobenzyl)oxy]ethyl}-1,3-thiazol-2-aminium chloride 
• 1357620-87-1 4-[2-(benzyloxy)ethyl]-1,3-thiazol-2-aminium chloride 
• 1357621-27-2 N-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-{4-[2-(3-pyridinylmethoxy)ethyl]-1,3-thiazol-2-yl}urea 
• 1357621-26-1 [4-(5-{[({4-[2-(benzyloxy)ethyl]-1,3-thiazol-2-yl}amino)carbonyl]amino}-3-cyclopentyl-1H-pyrazol-1-yl)phenyl]acetic acid 
• 1357621-25-0 [3-(5-{[({4-[2-(benzyloxy)ethyl]-1,3-thiazol-2-yl}amino)carbonyl]amino}-3-tert-butyl-1H-pyrazol-1-yl)phenyl]acetic acid 
• 1357621-24-9 [3-(5-{[({4-[2-(benzyloxy)ethyl]-1,3-thiazol-2-yl}amino)carbonyl]amino}-3-cyclopentyl-1H-pyrazol-1-yl)phenyl]acetic acid 
• 1357621-22-7 [4-(5-{[({4-[2-(benzyloxy)ethyl]-1,3-thiazol-2-yl}amino)carbonyl]amino}-3-tert-butyl-1H-pyrazol-1-yl)phenyl]acetic acid 
• 1357621-21-6 [3-(5-{[({4-[2-(benzyloxy)ethyl]-1,3-thiazol-2-yl}amino)carbonyl]amino}-3-cyclopropyl-1H-pyrazol-1-yl)phenyl]acetic acid 

Relevant articles and documents

Acyclic nucleoside phosphonates with 2-aminothiazole base as inhibitors of bacterial and mammalian adenylate cyclases

A series of novel acyclic nucleoside phosphonates (ANPs) was synthesized as potential adenylate cyclase inhibitors, where the adenine nucleobase of adefovir (PMEA) was replaced with a 5-substituted 2-aminothiazole moiety. The design was based on the structure of MB05032, a potent and selective inhibitor of fructose 1,6-bisphosphatase and a good mimic of adenosine monophosphate (AMP). From the series of eighteen novel ANPs, which were prepared as phosphoroamidate prodrugs, fourteen compounds were potent (single digit micromolar or submicromolar) inhibitors of Bordetella pertussis adenylate cyclase toxin (ACT), mostly without observed cytotoxicity in J774A.1 macrophage cells. Selected phosphono diphosphates (nucleoside triphosphate analogues) were potent inhibitors of ACT (IC50 as low as 37 nM) and B. anthracis edema factor (IC50 as low as 235 nM) in enzymatic assays. Furthermore, several ANPs were found to be selective mammalian AC1 inhibitors in HEK293 cell-based assays (although with some associated cytotoxicity) and one compound exhibited selective inhibition of mammalian AC2 (only 12% of remaining adenylate cyclase activity) but no observed cytotoxicity. The mammalian AC1 inhibitors may represent potential leads in development of agents for treatment of human inflammatory and neuropathic pain.

QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS

Compounds of formula (Ι') that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF

The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (I). wherein R1, R2, R3, R4, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (II). wherein R1a, R2a, Rx, and n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.